Literature DB >> 8548021

High-performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma.

H Sumiyoshi1, Y Fujiwara, T Ohune, N Yamaoka, K Tamura, M Yamakido.   

Abstract

A simplified method for the simultaneous determination of irinotecan (CPT-11, I) and its active metabolite (SN-38, II) in human plasma by high-performance liquid chromatography (HPLC) with fluorescence detection has been developed. Following the addition of the internal standard (I.S.) camptothecin, the drugs were extracted from plasma using methanol. The average extraction efficiencies were 87% for I, 90% for II and 90% for the I.S. Chromatography was performed using a TSK gel ODS-80Ts column, monitored at 556 nm (excitation wavelength, 380 nm) and the mobile phase was acetonitrile-50 mM disodium hydrogen phosphate (28:72) containing 5 mM heptanesulphonate (pH 3.0). The linear quantitation ranges for I and II were 30-2000 and 1-30 ng/ml, respectively.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8548021     DOI: 10.1016/0378-4347(95)00130-1

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  6 in total

1.  Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization.

Authors:  Xiaohong Chen; Cody J Peer; Raul Alfaro; Tian Tian; Shawn D Spencer; William D Figg
Journal:  J Pharm Biomed Anal       Date:  2012-01-16       Impact factor: 3.935

Review 2.  Clinical pharmacokinetics of irinotecan.

Authors:  G G Chabot
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

3.  Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.

Authors:  M Ando; K Eguchi; T Shinkai; T Tamura; Y Ohe; N Yamamoto; T Kurata; T Kasai; H Ohmatsu; K Kubota; I Sekine; N Hojo; T Matsumoto; T Kodama; R Kakinuma; Y Nishiwaki; N Saijo
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro.

Authors:  T Takahashi; Y Fujiwara; M Yamakido; O Katoh; H Watanabe; P I Mackenzie
Journal:  Jpn J Cancer Res       Date:  1997-12

5.  Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1*6 or UGT1A1*28.

Authors:  Chuan Tian; Haifeng Ying; Rongyuan Zhuang; Xiaowei Zhang; Hongmin Lu; Hui Wang; Shuowen Wang; Qi Li; Chungang Wang; Xun Cai
Journal:  Cancer Manag Res       Date:  2018-11-22       Impact factor: 3.989

6.  Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.

Authors:  Xun Cai; Weiguo Cao; Honghua Ding; Tianshu Liu; Xinli Zhou; Mei Wang; Ming Zhong; Ziyi Zhao; Qing Xu; Liwei Wang
Journal:  J Cancer Res Clin Oncol       Date:  2013-07-28       Impact factor: 4.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.